Keywords
Hyperthermyc intraperitoneal chemotherapy
HIPEC
Cytoreduction
Peritoneal carcinomatosis
Hemodinamyc monitoring
HIPEC
Cytoreduction
Peritoneal carcinomatosis
Hemodinamyc monitoring
Categories
How to Cite
1.
Videla C, Di Stefano S. Perioperative management of surgery debulking with chemotherapy hyperthermic intraperitoneal. Rev Arg de Ter Int. [Internet]. 2021 Jan. 20 [cited 2024 Jul. 3];38:e708.16092020. Available from: https://revista.sati.org.ar/index.php/MI/article/view/708
Abstract
Peritoneal carcinomatosis is defined as tumor dissemination within the abdominal cavity secondary to the growth of tumors on the peritoneal surface or visceral organs. This condition, regardless of the origin of the primary tumor, is usually associated with the progression of the underlying oncological disease and carries a worse short-term prognosis. In recent years, the better understanding of the pathways of tumor spread associated with the protective function of the peritoneal barrier against cancer spread has led to peritoneal carcinomatosis being considered a locoregional disease. Consequently, new therapeutic strategies have emerged that combine cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in patients suffering from peritoneal carcinomatosis secondary to tumors of appendicular, gastrointestinal, gynecological origin and peritoneal mesothelioma, with promising results in terms of prolonged survival. .
The objective of this monograph is to make a bibliographic review of the perioperative management of patients who undergo debulking surgery associated with hyperthermic intraperitoneal chemotherapy and to explain the physiological foundations with the possible complications of this procedure associated with hemodynamic, respiratory and metabolic changes.
References
1. Coccolini F., Gheza F., Lotti M., et al. - “Peritoneal carcinomatosis.” World J Gastroenterol. 2013 Nov 7; 19 (41): 6979–6994.
2. Sugarbaker PH. “Peritonectomy procedures.” Ann Surg 1995; 221: 29-42.
3. Rothfield, Kenneth P., Crowley K. “Anesthesia Considerations during Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.” Surgical Oncology Clinics of North America. 2012. 21 (4): 533–41.
4. Jafari, Mehraneh D., Halabi W., et al. “Surgical Outcomes of Hyperthermic Intraperitoneal Chemotherapy: Analysis of the American College of Surgeons National Surgical Quality Improvement Program.” JAMA Surgery. 2014. 149 (2): 170–75.
5. Padmakumar A. “Intensive Care Management of Patient After Cytoreductive Surgery and HIPEC - A Concise Review.” Indian Journal of Surgical Oncology. 2016. 7 (2): 244–48.
6. Elias D., Gilly F., Boutitie F., et al. “Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study” J Clin Oncol. 2010. 28 (1):63-68.
7. Yan T., Black D, Savady R, Sugarbaker P. “ Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma” J Clin Oncol. 2006. 24: 4011-4019.
8. Sugarbaker P. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: Progress toward a new standard of care” Cancer Treat Rev. 2016 Jul;48:42-9.
9. Wright A., Cronin A., Milne D., et al. “Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer” J Clin Oncol. 2015 Sep 10;33(26):2841-7.
10. Yan T., Black D., Savady R., Sugarbaker P. “A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei” Annals of Surgical Oncology. 2007. 14(2):484–492.
11. Yan T., Welch L., Black D., Sugarbaker P. “A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma” Annals of Oncology. 2007. 18: 827–834.
12. Königsrainer I., Beckert S. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?” World J Gastroenterol 2012; 18(38): 5317-5320.
13. Glehen O., Cotte E., Kusumara S., et al. “Hyperthermic Intraperitoneal Chemotherapy: Nomenclature and Modalities of Perfusion” Journal of Surgical Oncology 2008; 98: 242–246.
14. Bree E. “Optimal drugs for HIPEC in different tumors” JBUON 2015; 20 (Suppl. 1): S40-S46.
15. Lemoine L., Sugarbaker P., Van der Speeten K. “Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma.” International Journal of Hyperthermia, 2017. 33(5):1-34
16. Brucher B., Piso P., Verwaal V., et al “Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC -Overview and Basics” Cancer Investigation 2012, 30:209–224
17. Esquivel J., Angulo F., Bland R., Stephens A., Sugarbaker “Hemodynamic and Cardiac Function Parameters During Heated Intraoperative Intraperitoneal Chemotherapy Using the Open “Coliseum Technique” Annals of Surgical Oncology, 2000. 7(4):296–300
18. Colantonio L., Claroni C., Fabrizi L., et al. ¨A Randomized Trial of Goal Directed vs Standard Fluid Therapy in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy” J Gastrointest Surg. 2015, 19:722–729.
19. Schulermann C., Hoeppner J., Benk C., Schmidt R., Loop T., Kalbhenn J.”Intra-abdominal pressure, Cardiac Index and vascular resistance during hyperthermic intraperitoneal chemotherapy: a prospective observational study “ Minerva Anestesiologica 2016 February; 82 (2):160-9.
20. Raspe C., Flother L., Schneider R., Bucher M., Piso P. “Best practice for perioperative management of patients with cytoreductive surgery and HIPEC” EJSO. 2017, (43) 1013 - 1027.
21. Pret V.i, Chang D., Sugarbaker P. “Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients” Gastroenterology Research and Practice. 2012, Article ID 635314.
22. Ferreyra, G. et al. “Continuous positive airway pressure for treatment of respiratory complications after abdominal surgery: a systematic review and meta-analysis. “ Ann. Surg. 2008. 247, 617–626.
23. Arakelian E, Gunningberg L, Larsson J, Norlén K, Mahteme H.” Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.” Eur J Surg Oncol. 2011 Oct; 37(10):897-903.
24. Ljungqvist O., Scott M., Fearon K.. “Enhanced Recovery After Surgery. A Review” JAMA Surg. 2017;152(3):292-298.
25. Osseis M., Weyrech J., Gayat E., et al. “Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients” EJSO. 2016 (42) 1938 - 1942.
26. Vashi P., Gupta D., Lammersfeld C., et al.. “The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy” Nutrition Journal 2013, 12:118
Singer P., Blaser A., Berger M et al. “ESPEN guideline on clinical nutrition in the intensive care unit” Clinical Nu
2. Sugarbaker PH. “Peritonectomy procedures.” Ann Surg 1995; 221: 29-42.
3. Rothfield, Kenneth P., Crowley K. “Anesthesia Considerations during Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.” Surgical Oncology Clinics of North America. 2012. 21 (4): 533–41.
4. Jafari, Mehraneh D., Halabi W., et al. “Surgical Outcomes of Hyperthermic Intraperitoneal Chemotherapy: Analysis of the American College of Surgeons National Surgical Quality Improvement Program.” JAMA Surgery. 2014. 149 (2): 170–75.
5. Padmakumar A. “Intensive Care Management of Patient After Cytoreductive Surgery and HIPEC - A Concise Review.” Indian Journal of Surgical Oncology. 2016. 7 (2): 244–48.
6. Elias D., Gilly F., Boutitie F., et al. “Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study” J Clin Oncol. 2010. 28 (1):63-68.
7. Yan T., Black D, Savady R, Sugarbaker P. “ Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma” J Clin Oncol. 2006. 24: 4011-4019.
8. Sugarbaker P. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: Progress toward a new standard of care” Cancer Treat Rev. 2016 Jul;48:42-9.
9. Wright A., Cronin A., Milne D., et al. “Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer” J Clin Oncol. 2015 Sep 10;33(26):2841-7.
10. Yan T., Black D., Savady R., Sugarbaker P. “A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei” Annals of Surgical Oncology. 2007. 14(2):484–492.
11. Yan T., Welch L., Black D., Sugarbaker P. “A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma” Annals of Oncology. 2007. 18: 827–834.
12. Königsrainer I., Beckert S. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?” World J Gastroenterol 2012; 18(38): 5317-5320.
13. Glehen O., Cotte E., Kusumara S., et al. “Hyperthermic Intraperitoneal Chemotherapy: Nomenclature and Modalities of Perfusion” Journal of Surgical Oncology 2008; 98: 242–246.
14. Bree E. “Optimal drugs for HIPEC in different tumors” JBUON 2015; 20 (Suppl. 1): S40-S46.
15. Lemoine L., Sugarbaker P., Van der Speeten K. “Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma.” International Journal of Hyperthermia, 2017. 33(5):1-34
16. Brucher B., Piso P., Verwaal V., et al “Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC -Overview and Basics” Cancer Investigation 2012, 30:209–224
17. Esquivel J., Angulo F., Bland R., Stephens A., Sugarbaker “Hemodynamic and Cardiac Function Parameters During Heated Intraoperative Intraperitoneal Chemotherapy Using the Open “Coliseum Technique” Annals of Surgical Oncology, 2000. 7(4):296–300
18. Colantonio L., Claroni C., Fabrizi L., et al. ¨A Randomized Trial of Goal Directed vs Standard Fluid Therapy in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy” J Gastrointest Surg. 2015, 19:722–729.
19. Schulermann C., Hoeppner J., Benk C., Schmidt R., Loop T., Kalbhenn J.”Intra-abdominal pressure, Cardiac Index and vascular resistance during hyperthermic intraperitoneal chemotherapy: a prospective observational study “ Minerva Anestesiologica 2016 February; 82 (2):160-9.
20. Raspe C., Flother L., Schneider R., Bucher M., Piso P. “Best practice for perioperative management of patients with cytoreductive surgery and HIPEC” EJSO. 2017, (43) 1013 - 1027.
21. Pret V.i, Chang D., Sugarbaker P. “Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients” Gastroenterology Research and Practice. 2012, Article ID 635314.
22. Ferreyra, G. et al. “Continuous positive airway pressure for treatment of respiratory complications after abdominal surgery: a systematic review and meta-analysis. “ Ann. Surg. 2008. 247, 617–626.
23. Arakelian E, Gunningberg L, Larsson J, Norlén K, Mahteme H.” Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.” Eur J Surg Oncol. 2011 Oct; 37(10):897-903.
24. Ljungqvist O., Scott M., Fearon K.. “Enhanced Recovery After Surgery. A Review” JAMA Surg. 2017;152(3):292-298.
25. Osseis M., Weyrech J., Gayat E., et al. “Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients” EJSO. 2016 (42) 1938 - 1942.
26. Vashi P., Gupta D., Lammersfeld C., et al.. “The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy” Nutrition Journal 2013, 12:118
Singer P., Blaser A., Berger M et al. “ESPEN guideline on clinical nutrition in the intensive care unit” Clinical Nu
The magazine does not retain the reproduction rights (copyright) so the authors can republish their works with the sole mention of the original publication source.